Document:

lxrp_ex103.htm

EXHIBIT 10.3
  
 	 
	 National Research Council 
	 Conseil national de recherches 
	 Master Collaborative

	 Canada 
	 Canada 
	 Research Agreement

 
 
 
 
  
 	 BETWEEN:
	 NATIONAL RESEARCH COUNCIL OF CANADA

	   
	 whose head office address is: 

 
 
 
 
  
 	  
	 1200 Montreal Road 
	
	  
	 Ottawa, Ontario K1A 0R6 
	 (called “NRC”) 

 
 
 
 
  
 	 AND:
	 LEXARIA CANPHARM CORP.

	   
	 a corporation under the laws of Canada 

	   
	 whose address is: 

 
 
 
 
  
 	  
	 156 Valleyview Road 
	
	  
	 Kelowna, British Columbia V1X 3M4 
	 (called the “Collaborator”)

 
 
 
 
  
 (Collectively known as the “Parties”) 
  
 WHEREAS the Parties have common interests in the development of specialty and functional ingredients for differentiated consumer markets involving functional food, nutrition, and health and wellness applications; 
  
 WHEREAS the Parties share expertise in fatty acid chemistry, product formulation and functional ingredient characterization, most notably cannabinoids and related active ingredients;
  
 WHEREAS the Parties recognize that this common interest creates a foundation for a strategic collaborative R&D relationship; and 
  
 WHEREAS the Parties wish to enter into a Master Collaborative Research Agreement (the “Agreement”) to establish the terms and conditions which will govern the collaboration. 
  
 NOW THEREFORE, in consideration of the mutual covenants hereunder, the Parties agree as follows: 
  
 	 1.
	 This Agreement concerns scientific research and development, called the "Collaboration", described as: Joint investigation of technical challenges and new opportunities associated with lipophilic active ingredient compositions. The Collaboration includes:

 
 
 
 
  
 	  
	 (a) 
	 Development of specific Projects to explore solutions for the technical challenges surrounding commercialization of LAA-BEA formulations, both those common to the industry as a whole and those specific to Collaborator’s proprietary processes;

			
	  
	 (b) 
	 Improvement of expertise and capacity in the area of ingredient formulation for improved function of cannabinoids and related high value bioactives; and

			
	  
	 (c) 
	 Identification and exploration of innovative new technologies and applications of mutual interest to NRC and Collaborator.

 
 
 
 
  
 	 2.
	 The Collaborator chooses to work with NRC because of NRC's unique capabilities, and does not expect NRC to perform work that would be in competition with Canadian firms. The name of NRC, or any reference to NRC, shall not be used in promotional activities of the Collaborator without NRC's prior written consent.

		  

	 3.
	 The Parties will contribute to the Collaboration by the performance of specific R&D projects (“Projects”) developed in line with the attached “ANNEX PO: Project Objectives and Overview” or by payments, or both.

		  

	 4.
	 Both Parties will contribute to the development of Projects based on mutual interest and objectives. Specific terms of each Project will be negotiated on a per Project basis; each Project shall be defined in a Project Annex (“PA”). Each PA will be in the form attached as Appendix 1 (“Project Annex”) and Appendix 2 (“Statement of Work and Deliverables”) and will be approved jointly by the Parties. Each PA is hereby incorporated herein by reference and made a part of this Agreement once duly signed by an authorized representative of each Party. A PA can only be amended by a written amendment signed by an authorized representative of each Party.

		  

	 5.
	 This Agreement is subject to the terms in the attached “Annex GC: General Conditions”.

 
 
 
 
  
 	 (2016) 
	 Page 1 of 14
	 NRC: ACRD: BSC 

		   
	 Business Confidential - Protected B 

 
 
 
 
 	 
	
	

	 

 
 
 
 
  
 	 
	 National Research Council 
	 Conseil national de recherches 
	 Master Collaborative

	 Canada 
	 Canada 
	 Research Agreement

 
 
 
 
  
 	 6.
	 The total price of the Collaboration is not to exceed $250,000 plus applicable taxes.

		  

	 7.
	 The Collaborator shall pay to NRC in cash a total sum not to exceed $125,000 to be paid in accordance with individual PA. The Collaborator shall also pay applicable taxes. *

		  

	 8.
	 NRC shall make a co-investment to the Collaboration by performing, at its own cost, work described in the Statement of Work and Deliverables of applicable PA at a total value not to exceed $125,000.

		  

	 9.
	 This Agreement shall become effective on the date the Agreement is signed by both Parties and expires on June 29, 2018 (“Expiry Date”) unless terminated earlier. This Agreement shall remain in force relative to any PA in progress at the Expiry Date until those PA are completed or otherwise terminated. The following terms and conditions shall survive the termination or expiration of this Agreement:

 
 
 
 
  
 	  
	 (a) 
	 payment obligations which accrued while this Agreement was in force, or upon its termination, and the interest provisions of this Agreement;

			
	  
	 (b) 
	 the terms and conditions with respect to Intellectual Property which are found in the attached Annex IU entitled “Annex IU: Intellectual Property” that forms part of this Agreement; and

			
	  
	 (c) 
	 terms and conditions with respect to exclusion of certain liability, limited warranties, and dispute resolution, all of which are found in the attached General Conditions that form part of this Agreement.

 
 
 
 
  
 	 10.
	 This Agreement shall be interpreted according to the laws of the Province of Ontario and the laws of Canada in force there. Subject to Article GC-15, for any litigation concerning this Agreement, including litigation arising from arbitration, the parties hereby irrevocably and unconditionally attorn to the exclusive jurisdiction of the Courts of the Province of Ontario, and all courts competent to hear appeals therefrom. The parties expressly exclude any conflict of laws rules or principles that might refer disputes under this Agreement to the laws of another jurisdiction.

		  

	 11.
	 This Agreement may be executed in one or more counterparts and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one valid and binding Agreement. A facsimile copy or portable document format (PDF) copy of an executed counterpart signature page will be as valid as an originally executed counterpart for purposes of signing this Agreement.

 
 
 
 
  
 SIGNED by the Collaborator in duplicate at Kelowna, British Columbia, Canada 
  
 			  
	 LEXARIA CANPHARMCORP.
	  

			  
		  
	  

	 Date: 
		  
	 Per: 
		  

	  
	 (dd-month-yyyy) 
	  
	  
	 John Docherty, President 
	  

 
 
 
 
  
 SIGNED by NRC in duplicate at Ottawa, Ontario, Canada 
  
 			  
	 NATIONAL RESEARCH COUNCIL OF CANADA
	  

			  
		  
	  

	 Date: 
		  
	 Per: 
		  

	  
	 (dd-month-yyyy) 
	  
	  
	 Dr. Roman Szumski, Vice-President, Life Sciences 
	  

 
 
 
 
 ____________________
 	 * 
	 Sales Tax (GST or similar) : NRC registration number 121 491 807 

	  
	 Quebec Sales Tax : NRC registration number 1006 178 088

 
 
 
 
  
 	 (2016) 
	 Page 2 of 14
	 NRC: ACRD: BSC 

		   
	 Business Confidential - Protected B 

 
 
 
 
 	 
	
	

	 

 
 
 
 
  
 	 
	 National Research Council 
	 Conseil national de recherches 
	 Master Collaborative

	 Canada 
	 Canada 
	 Research Agreement

 
 
 
 
  
 ANNEX GC: GENERAL CONDITIONS
  
 	 GC-2
	 INTERPRETATION OF AGREEMENT: This Agreement supersedes all prior communications, negotiations and agreements concerning the Collaboration. No amendment or waiver of terms in this Agreement, including the annexes thereto, is effective unless it is in writing, signed by all Parties. In case of inconsistency between this Agreement and any PA, this Agreement prevails. No forbearance by a Party implies any broader, continuing, or future forbearance. If a court finds part of this Agreement invalid, the remainder is valid in accordance with its most reasonable interpretation. This Agreement does not create a relationship of agency, employment, partnership, or joint venture. 

		  

	 GC-3
	 ASSIGNMENT: This Agreement, and any licence granted pursuant to it, is personal to the Parties, so that neither its assignment, nor its assumption by a corporation formed by amalgamation of a Party with a third party, is valid except by written consent of all Parties, which consent shall not be unreasonably withheld. 

		  

	 GC-4
	 EXCLUSION OF CERTAIN LIABILITY: No Party shall be liable for failure or delay in performance caused by circumstances beyond its reasonable control, or for incorrectness or inaccuracy of data supplied, advice given, or opinions expressed. No claim may be made for indirect, consequential, or incidental damages. 

		  

	 GC-5
	 LIMITED WARRANTIES: Each Party warrants that it will conduct the Collaboration work in a professional manner conforming to generally accepted practices for scientific research and development. However, because of the nature of such work, no specific result is promised. 

 
 
 
 
  
 	  
	 5.1
	 No Party warrants that technical information conveyed in the deliverables does not infringe the rights of third parties under a present or future patent.

			
	  
	 5.2
	 No Party warrants the validity of patents under which rights may be granted pursuant to this Agreement, or makes any representation as to the scope of patents or that those inventions may be exploited without infringing the rights of others.

 
 
 
 
  
 	 GC-6
	 VISITS: Subject to reasonable notice of the number and names and status of personnel, including employees, students and other persons working on behalf of another Party and other requirements under this Agreement, a Party may, in its discretion, permit visits to its premises by one or more of another Party's personnel, if relevant to the Collaboration and not likely to interfere with regular operations. 

		   

	 GC-7
	 TERMINATION FOR COST OVERRUNS: Following notification by one Party that costs expressed as estimates for a specific PA will be exceeded by more than 10%, if the Parties do not amend the PA within sixty (60) days, then upon the expiration of that period the specific PA shall be terminated. Upon such termination: 

 
 
 
 
  
 	  
	 (a) 
	 each Party shall pay the other Party any costs pre-dating the effective date of the termination that were intended to be reimbursable under the PA;

			
	  
	 (b) 
	 any licence or option granted under the PA to any Party is also terminated;

			
	  
	 (c) 
	 confidentiality obligations of each Party regarding the information that is part of its Arising IP under the PA are terminated, both Parties continuing to be bound by all other confidentiality obligations under this Agreement.

 
 
 
 
  
 	 GC-7
	 TERMINATION FOR CAUSE: This Agreement or any PA under this Agreement may be terminated for cause as follows: 

 
 
 
 
  
 	  
	 (a) 
	 by either Party if the other Party defaults in performance of any obligation under this Agreement or any PA and fails to cure the default within thirty (30) days after receipt of written notice of default, and termination will take effect at the expiration of the cure period;

			
	  
	 (b) 
	 by NRC forthwith if the other Party becomes bankrupt or has a receiver appointed to continue its operations, or passes a resolution for winding up;

			
	  
	 (c) 
	 by NRC forthwith if the other Party has made a false or misleading representation or warranty;

 
 
 
 
  
 	 (2016) 
	 Page 3 of 14
	 NRC: ACRD: BSC 

		   
	 Business Confidential - Protected B 

 
 
 
 
 	 
	
	

	 

 
 
 
 
  
 	 
	 National Research Council 
	 Conseil national de recherches 
	 Master Collaborative

	 Canada 
	 Canada 
	 Research Agreement

 
 
 
 
   
 	  
	 (d) 
	 upon termination for cause:

 
 
 
 
  
 	  
	 (i) 
	 in the case of termination of this Agreement, all PA shall terminate concurrently;

			
	  
	 (ii) 
	 each Party shall pay the other Party any costs pre-dating the effective date of the termination that were intended to be reimbursable under this Agreement or a PA;

			
	  
	 (iii) 
	 the defaulting Party shall also pay the terminating Party any incurred costs that result directly from the cancellation of obligations and from uncancellable obligations;

			
	  
	 (iv) 
	 any licence or option granted under this Agreement or a PA to the defaulting Party is terminated;

			
	  
	 (v) 
	 confidentiality obligations of each Party regarding the information that is part of its Arising IP are terminated, both Parties continuing to be bound by all other confidentiality obligations under this Agreement or a PA.

 
 
 
 
  
 	 GC-8
	 EARLY TERMINATION OF A PA: Early termination of a PA by either Party shall not affect the ongoing validity of this Agreement or any other PA hereunder. 

		  

	 GC-9
	 NOTICES: Any notice related to this Agreement, including a notice of change of address, must be sent to the addresses stated at the beginning of this Agreement, either by registered mail, which is deemed to be effective notice five days after mailing, or by courier or facsimile, which are effective notices only when acknowledged by a courier's delivery receipt or by a specific non-automatic return facsimile transmission. 

		  

	 GC-10
	 CONDITIONS: The other Party agrees that if there is any research work in the Collaboration involving human subjects, human tissues, laboratory animals, or animal tissues, it shall not proceed without prior approval of NRC’s Human Subjects Research Ethics Committee or Animal Care Committee and shall not be conducted in contravention of the respective Committee’s conditions of approval. 

		  

	 GC-11
	 NO BRIBES: The other Party represents and warrants to NRC that no bribe, gift, reward, benefit or other inducement has been or will be paid, given, promised or offered directly or indirectly to any federal government official or employee or to a member of the family of such person, with a view to influencing the entry into this Agreement or the administration of this Agreement. 

		  

	 GC-12
	 NO DIRECT BENEFIT: The other Party represents and warrants to NRC that the following individuals shall not derive a direct benefit from this Agreement: 

 
 
 
 
  
 	  
	 (a) 
	 a current or former public office holder who is not in compliance with the Conflict of Interest Act, 2006, c.9, s.2;

			
	  
	 (b) 
	 a current or former member of the House of Commons who is not in compliance with the Conflict of Interest Code for Members of the House of Commons;

			
	  
	 (c) 
	 a current or former public servant who is not in compliance with the Values and Ethics Code for the Public Service;or

			
	  
	 (d) 
	 a current or former NRC employee who is not in compliance with NRC’s Conflict of Interest Policy.

 
 
 
 
  
 	 GC-13
	 NO MISREPRESENTATION: The other Party represents and warrants to NRC that it, including its Directors, officers, employees or agents, has made no material misrepresentation, whether by omission or commission, with a view to the obtaining of this Agreement. 

		   

	 GC-14
	 NO CONTINGENCY FEE: The other Party represents and warrants to NRC that it has not directly or indirectly paid or agreed to pay and that it will not directly or indirectly pay a contingency fee for the solicitation, negotiation or obtaining of this Agreement to any person, other than an employee acting in the normal course of the employee’s duties. In this section, “contingency fee” means any payment or other compensation that depends or is calculated based on the degree of success in soliciting, negotiating or obtaining this Agreement and “person” includes any individual who is required to file a return with the registrar pursuant to the Lobbying Act, R.S.C.,1985,c. 44 (4th Supplement) as amended.

 
 
 
 
  
 	 (2016) 
	 Page 4 of 14
	 NRC: ACRD: BSC 

		   
	 Business Confidential - Protected B 

 
 
 
 
 	 
	
	

	 

 
 
 
 
  
 	 
	 National Research Council 
	 Conseil national de recherches 
	 Master Collaborative

	 Canada 
	 Canada 
	 Research Agreement

 
 
 
 
  
 	 GC-15
	 PERSONNEL: The other Party shall be liable for the actions of its personnel, including its employees, contractors, agents or students and shall ensure that while working on NRC premises, they are required to comply with the following requirements: 

 
 
 
 
  
 	  
	 (a) 
	 regulations, policies and directives that NRC may adopt from time to time to address access to NRC facilities and activities thereon, and without limiting the generality of the foregoing, regulations, policies and directives addressing:

 
 
 
 
  
 	  
	 (i) 
	 protection of confidential information;

			
	  
	 (ii) 
	 information management and information technology (IM/IT);

			
	  
	 (iii) 
	 harassment and code of conduct in NRC facilities;

			
	  
	 (iv) 
	 protection of safety and health of NRC employees, the other Party’s personnel and others; and

			
	  
	 (v) 
	 security and emergency procedures;

 
 
 
 
  
 	  
	 (b) 
	 any and all security policies that the Government of Canada may promulgate from time to time including:

 
 
 
 
  
 	  
	 (i) 
	 any and all security conditions and requirements NRC may request from time to time including, without limitation, undergoing a security screening, which may include a fingerprint check and if, following a security screening, an employee of the Collaborator is unable to obtain or maintain a level of security clearance that, in the sole opinion of NRC, is adequate, such employee of the Collaborator will be denied access to NRC facilities and IT Resources;

			
	  
	 (ii) 
	 the requirement to display an identification badge as a condition of access to NRC facilities with or without restrictions on hours of access;

			
	  
	 (iii) 
	 restrictions on access to NRC’s IT Resources; “NRC’s IT Resources” include, but are not limited to, all computers, telecommunications systems, workstations, PCs, laptops, storage, software, peripheral devices, servers, network equipment, transmission equipment, Remote Access Systems, and internal and external communications systems -- such as the Internet, e-mail and Intranet -- e-mail accounts, messages and associated files created, sent received, or stored on NRC IT resources; and

			
	  
	 (iv) 
	 the requirement to follow security procedures at all times and not to do anything that may compromise the integrity of NRC facilities or NRC IT Resources, with NRC reserving the right to modify or terminate the access privileges of the Collaborator’s personnel at any time;

 
 
 
 
  
 	  
	 (c) 
	 all confidentiality obligations under this Agreement.

 
 
 
 
  
 	  
	 NRC shall provide the other Party with access to all relevant legislation, regulations, policies and procedures as well as notice of any changes, and shall provide security, health and safety training to the Collaborator’s personnel as soon as possible following permitted access to NRC facilities. 

		  

	 GC-16
	 DISPUTE RESOLUTION: Disputes concerning this Agreement shall not be litigated. All disputes arising in connection with this Agreement which cannot be resolved through negotiations to the mutual satisfaction of both Parties within thirty (30) days, or such longer period as may be mutually agreed upon, may be submitted by either Party to arbitration in accordance with the Commercial Arbitration Act of Canada, R.S.C., 1985, c. 17 (2nd Supp.), as amended, and shall be subject to the following: 

 
 
 
 
  
 	  
	 (a) 
	 The Party requesting such arbitration shall do so by written notice to the other Party.

			
	  
	 (b) 
	 The arbitration shall take place in Ottawa, Ontario before a single arbitrator to be chosen jointly by the Parties. Failing agreement of the Parties on a single arbitrator within thirty (30) days of such notice requesting arbitration, either party may apply to a judge of a court having jurisdiction in Ottawa, Ontario for the appointment of a single arbitrator. 

 
 
 
 
   
 	 (2016) 
	 Page 5 of 14
	 NRC: ACRD: BSC 

		   
	 Business Confidential - Protected B 

 
 
 
 
 	 
	
	

	 

 
 
 
 
  
 	 
	 National Research Council 
	 Conseil national de recherches 
	 Master Collaborative

	 Canada 
	 Canada 
	 Research Agreement

 
 
 
 
  
 	  
	 (c) 
	 Each Party shall pay its own costs and an equal share of all of the costs of the arbitration and the fees of the arbitrator, except for the exceptional circumstance in which an arbitral award may require the payment of all costs by a Party who has brought a plainly frivolous dispute.

			
	  
	 (d) 
	 The arbitrator shall issue a written decision as soon as practicable after the conclusion of the final hearing, but in any event no later than sixty (60) days thereafter, unless that time period is extended for a fixed period by the Arbitrator on written notice to each Party because of illness or other cause beyond the Arbitrator’s control. The decision shall be rendered in such form that judgment may be entered thereon in any court having jurisdiction.

			
	  
	 (e) 
	 The decision shall be final and binding on the Parties in accordance with the Commercial Arbitration Act of Canada.

 
 
 
 
  
 Neither Party may request arbitration in respect of a breach of this Agreement after the fourth anniversary of the day on which the requesting Party first discovered that breach, unless the other Party has agreed in writing to extend the period. 
  
 	 (2016) 
	 Page 6 of 14
	 NRC: ACRD: BSC 

		   
	 Business Confidential - Protected B 

 
 
 
 
 	 
	
	

	 

 
 
 
 
  
 	 
	 National Research Council 
	 Conseil national de recherches 
	 Master Collaborative

	 Canada 
	 Canada 
	 Research Agreement

 
 
 
 
  
 ANNEX PT: PAYMENT TERMS
  
 	 PT-1
	 Except for an amount expressed in a PA that is due upon signature of the PA, all amounts set out in a PA shall be due as invoiced by NRC, which invoice shall provide for payment due 30 days from the date the invoice is issued. An amount expressed in a PA to be due upon signature of the PA is due immediately upon execution of the PA by both Parties. 

		  

	 PT-2
	 NRC may suspend its performance of any obligations under this Agreement until the specified prepayment or payment is received, and for as long as any payments are in arrears. 

		  

	 PT-3
	 If a surplus of prepayment remains as a result of premature termination of a PA, it will be refunded. 

		  

	 PT-4
	 A Party shall notify the other Party, and explain, if it appears at any time that costs expressed as estimates will be exceeded by more than 10%. The Parties shall then negotiate a further agreement on costs or payments, and either Party may suspend the performance of any obligations, other than accrued obligations to pay, until a further agreement is reached. 

		  

	 PT-5
	 Payments must be made to: “Receiver General - National Research Council of Canada" and addressed to: 

 
 
 
 
  
 Accounts Receivable 
National Research Council of Canada 
1200 Montreal Road 
Ottawa, Ontario, K1A 0R6, Canada
  
 	 PT-6
	 Where an instrument tendered in payment or settlement of an amount due to NRC is, for any reason, dishonoured, an administrative charge of $25 is payable to NRC and is due as invoiced. 

		  

	 PT-7
	 Interest is payable on all overdue amounts. Interest on overdue amounts is calculated and compounded monthly at the average bank rate plus 3% and accrues during the period beginning on the due date and ending on the day before the day on which payment is received by NRC. For purposes of this paragraph “bank rate” means the rate of interest established periodically by the Bank of Canada as the minimum rate at which the Bank of Canada makes short term advances to members of the Canadian Payments Association, and “average bank rate” means the weighted arithmetic average of the bank rates that are established during the month before the month in respect of which interest is being calculated. 

 
 
 
 
  
 (Rateinformation may be found at http://www.bankofcanada.ca/rates/exchange/exchange-rates-in-pdf/ . This site provides information on the rate used by departments of the Government of Canada to calculate the interest on overdue accounts payable and is the same rate used by NRC to charge interest on overdue accounts receivable under the Interest and Administrative Charges Regulations, SOR/96-188. This web site address, and the information set out there, is provided here for convenience. In case of rate discrepancy, the rates quoted by the Bank of Canada shall prevail.)
  
 	 (2016) 
	 Page 7 of 14
	 NRC: ACRD: BSC 

		   
	 Business Confidential - Protected B 

 
 
 
 
 	 
	
	

	 

 
 
 
 
  
 	 
	 National Research Council 
	 Conseil national de recherches 
	 Master Collaborative

	 Canada 
	 Canada 
	 Research Agreement

 
 
 
 
  
 ANNEX IU: INTELLECTUAL PROPERTY
  
 	 IU-8
	 NATURE OF THE PROJECT: By the nature of the Collaboration, Arising Intellectual Property that may arise is difficult to predict, and the Parties consider it desirable to defer settling the terms on which it will be available until the Arising Intellectual Property is known. 

		   

	 IU-9
	 DEFINITIONS OF FIXED TERMS:

 
 
 
 
  
 	  
	 2.1
	 "Arising Intellectual Property" or “Arising IP” is Intellectual Property that is developed in the Collaboration and that is disclosed in the Deliverables of the individual PA. The possessive adjective “NRC’s” or “Collaborator’s” indicates ownership or control by a Party.

			
	  
	 2.2
	 "Commercially Exploit" is to use, reproduce and modify Arising IP, and to manufacture, use, import, and sell articles embodying or made by use of any Deliverables, and to provide services by use of any Deliverables.

			
	  
	 2.3
	 “Confidential Background Information” means any confidential or proprietary information, either of a business or technical nature, other than Arising IP, disclosed by one Party to the other Party pursuant to this Agreement.

			
	  
	 2.4
	 "Deliverables" are the tangible outcomes of the Collaboration, such as reports, physical models, samples, data records, drawings, and machine-readable software, that are specifically mentioned in the individual PA Statement of Work and Deliverables as being deliverable.

			
	  
	 2.5
	 “Intellectual Property” or “IP” is all rights in inventions (whether patentable or not), patents, copyright material, trade secrets, confidential information and bacterial, viral, plant, human, or animal material that has new genetic or other characteristics first produced by a Party.

			
	  
	 2.6
	 “Background Intellectual Property” or “Background IP” means any Intellectual Property existing prior to the commencement of this Agreement and/or developed outside the scope of the Collaboration.

 
 
 
 
  
 	 IU-3
	 ARISING INTELLECTUAL PROPERTY: The Parties represent that, by law or contract, they will own any Arising IP created by their employees, contractors, agents or students. A Party who is the sole owner of Arising IP is responsible for patenting and licensing its Arising IP, but is not obliged by this Agreement to patent its Arising IP. However, a Party who is unwilling to patent its Arising IP shall diligently do so if the other Party undertakes to pay all expenses incurred in obtaining and maintaining the patent. 

		  

	 IU-4
	 JOINTLY CREATED ARISING IP: In the case of Arising IP that was created by employees of both Parties, the Collaborator hereby assigns its entire rights in that Arising IP to NRC and agrees to execute and deliver any further documents and to give any further assurances that NRC may request. It will then be regarded as NRC’s Arising IP and that Arising IP shall be treated as NRC’s Arising IP for all purposes under this Agreement. 

		  

	 IU-5
	 SHARING INFORMATION: The Parties shall keep each other promptly informed of Arising IP. Each Party shall give the other, for information only, a copy of any patent application for Arising IP immediately upon filing the application, and a copy of related correspondence with a patent office if requested, and the information contained in such documents and correspondence will be maintained in confidence. 

		  

	 IU-6
	 LICENCE OF NRC’S ARISING IP: NRC, upon request by the Collaborator no later than (6) six months after the end of the applicable PA, agrees: 

 
 
 
 
  
 	  
	 (a) 
	 For any Arising IP that could not be Commercially Exploited without use of the Collaborator’s Background IP, to grant to Collaborator a sole, worldwide, perpetual license (with the right to sublicense) of the Arising IP to use, modify, adapt, and make derivative works for any purpose and to permit others to do any of the foregoing.

			
	  
	 (b) 
	 For all other Arising IP, to undertake to negotiate with the Collaborator in good faith to settle the terms of a sole licence which will allow the Collaborator to Commercially Exploit the Arising IP.

			
	  
	 (c) 
	 In addition, subject to confidentiality requirements, NRC hereby licenses the Collaborator under Crown copyright, free and without time limit, to use and reproduce all documents that are deliverable under the individual PA. 

 
 
 
 
  
 	 (2016) 
	 Page 8 of 14
	 NRC: ACRD: BSC 

		   
	 Business Confidential - Protected B 

 
 
 
 
 	 
	
	

	 

 
 
 
 
  
 	 
	 National Research Council 
	 Conseil national de recherches 
	 Master Collaborative

	 Canada 
	 Canada 
	 Research Agreement

 
 
 
 
  
 	 IU-7
	 LICENCE OF COLLABORATOR’S ARISING IP: Collaborator hereby grants to NRC a fully prepaid and royalty- free licence for all Collaborator’s Arising IP, solely for research purposes within NRC, for performing work under the Collaboration and for providing services to third parties while maintaining confidentiality as required under this Agreement. In addition, Collaborator, at NRC’s request, shall negotiate with NRC in good faith to settle the terms of a licence on terms financially and otherwise acceptable to the Collaborator, which will allow NRC to Commercially Exploit Collaborator’s Arising IP and to sub-licence third parties to Commercially Exploit Collaborator’s Arising IP only with the understanding that such exploitation or sub-licensing shall not compete against Collaborator’s commercial interests in the fields of cannabinoids, nicotine, non-steroidal anti-inflammatory drugs and vitamins. If the Parties cannot agree on such licence terms, the other Party agrees that it will not grant a licence to any third party under terms more favourable than those offered to NRC. Before entering into a licence, Collaborator shall promptly notify NRC of the proposed terms, and NRC shall have a right of first refusal to take a licence under such terms, which right must be exercised within 30 days of receipt of the proposed terms by NRC. 

		  

	 IU-8
	 BACKGROUND TECHNOLOGY: If, in order to perform work in the course of the Collaboration, a Party needs another Party’s Background IP, a licence for that limited purpose is granted by this Agreement and terminates at the end of the applicable PA. Upon completion of the applicable PA, if the use of a Party’s Background IP is required by the other Party to Commercially Exploit the Arising IP, a separate license for its use must be negotiated. 

		  

	 IU-9
	 CONFIDENTIAL BACKGROUND INFORMATION RESTRICTIONS: Unless otherwise stipulated in a separate agreement, the following provisions apply to Confidential Background Information that is in electronic, written, graphic or other tangible form, including a physical object, that is clearly marked “Proprietary” or “Confidential” or with an equivalent legend, or that is oral information provided that at the time of disclosure the disclosing Party clearly identifies the confidential nature of such information and confirms such confidential nature by transmitting the information, in a written version that is marked as above, to the receiving Party within 20 days of disclosure. The receiving Party agrees not to disclose any Confidential Background Information, including to any director, officer or employee of the receiving Party unless that individual needs the information to perform work in the course of the Collaboration and is legally bound to keep confidences. In protecting Confidential Background Information, the receiving Party must use at least the same degree of care as it uses to protect its own information of a similar nature, but not less than a reasonable degree of care. Unless specifically licensed, Confidential Background Information may only be used by the receiving Party to perform work in the course of a Project. These obligations of confidentiality and protection will initially apply to Confidential Background Information in the form of oral information but will cease to apply if the information is not provided in a written version within twenty (20) days of disclosure. Notwithstanding the foregoing, the receiving Party may disclose the particulars of this Agreement and its associated PA’s to others of its officers and employees for internal administrative and business purposes, to the extent that such disclosure does not result in a public release of such information. 

		  

	 IU-10
	 END OF CONFIDENTIAL BACKGROUND INFORMATION RESTRICTIONS: Unless otherwise stipulated in a separate agreement, all obligations of confidentiality and restrictions on the use of Confidential Background Information in this Agreement cease to apply five (5) years after the expiration of this Agreement and such obligations and restrictions do not apply to information that can be proved to be: 

 
 
 
 
  
 	  
	 (a) 
	 independently developed by the receiving Party without reference to or use of the confidential information of the other Party;

			
	  
	 (b) 
	 received from a third party without breach of any obligation of confidentiality;

			
	  
	 (c) 
	 in the public domain at the time of its disclosure or that later enters the public domain without breach of this Agreement; or

			
	  
	 (d) 
	 required to be disclosed by law, including, in the case of NRC, the Access to Information Act, provided that the receiving Party first provides the other Party with notice of such requirements and of its intent to disclose the information.

 
 
 
 
  
 	 (2016) 
	 Page 9 of 14
	 NRC: ACRD: BSC 

		   
	 Business Confidential - Protected B 

 
 
 
 
 	 
	
	

	 

 
 
 
 
  
 	 
	 National Research Council 
	 Conseil national de recherches 
	 Master Collaborative

	 Canada 
	 Canada 
	 Research Agreement

 
 
 
 
  
 	 IU-11
	 CONFIDENTIALITY AND USE OF ARISING IP: All Arising IP will be maintained in confidence and protected by both Parties with at least the same degree of care as they use to protect their own confidential information, but not less than a reasonable degree of care. Arising IP shall not be disclosed except: 

 
 
 
 
  
 	  
	 (a) 
	 as required for a patent application or for a license to a third party including disclosure to prospective licensees;

			
	  
	 (b) 
	 if the Arising IP has entered the public domain without breach of this Agreement;

			
	  
	 (c) 
	 as required to be disclosed by law, including, in the case of NRC, the Access to Information Act, provided that the receiving Party first provides the other Party with notice of such requirements and of its intent to disclose information; or

			
	  
	 (d) 
	 as otherwise agreed to by the Parties.

 
 
 
 
  
 	 IU-12
	 PUBLICITY: A Party may publicize the results of the Collaboration, to the extent permitted by confidentiality, and in so doing will acknowledge each Party's contribution. No Party will publicly suggest that the other Party endorses or recommends any product or process or results of the Collaboration. 

		  

	 IU-13
	 NO IMPLIED WARRANTIES: NRC’s Arising IP is supplied and licensed on a “as is” basis, and there are no representations, warranties or conditions, express or implied by statute, including without limitation any with respect to: 

 
 
 
 
  
 	  
	 (a) 
	 market readiness, merchantability, or fitness for any use or purpose;

			
	  
	 (b) 
	 operational state, character, quality, or freedom from defects;

			
	  
	 (c) 
	 validity of patents;

			
	  
	 (d) 
	 non-infringement of rights of third parties under present or future patents.

 
 
 
 
  
 	 IU-14
	 NO CONTESTATION OF VALIDITY: The Parties acknowledge the validity of the patents and copyright, if any licensed hereunder and agrees not to contest such validity, either directly or indirectly by assisting other parties. 

		  

	 IU-15
	 INDEMNITY: NRC rejects all liability and responsibility relating to the consequences of Collaborator using NRC’s Arising IP. Collaborator shall indemnify and save harmless NRC, its employees and agents from and against, and be responsible for: 

 
 
 
 
  
 	  
	 (a) 
	 all claims, demands, losses, damages, costs including solicitor and client costs, actions, suits or proceedings brought by any third party, that are in any manner based upon, arising out of, related to, occasioned by, or attributable to:

 
 
 
 
  
 	  
	 (i) 
	 the use by Collaborator of NRC’s Arising IP including without limitation, the manufacturing, distribution, shipment, offering for sale, sale, or use of products and services derived from NRC’s Arising IP; and

			
	  
	 (ii) 
	 product liability and infringement of Intellectual Property rights other than copyright, if any, licensed hereunder.

 
 
 
 
  
 	  
	 (b) 
	 other costs, including extra-judicial costs, of NRC defending such any action or proceeding, which NRC shall have the right to defend with counsel of its choice.

 
 
 
 
  
 This clause shall survive expiration or termination of this Agreement. 
  
 	 (2016) 
	 Page 10 of 14
	 NRC: ACRD: BSC 

		   
	 Business Confidential - Protected B 

 
 
 
 
 	 
	
	

	 

 
 
 
 
  
 	 
	 National Research Council 
	 Conseil national de recherches 
	 Master Collaborative

	 Canada 
	 Canada 
	 Research Agreement

 
 
 
 
  
 ANNEX PO: PROJECT OBJECTIVES AND OVERVIEW 
  
 Background 
One strategy to increase the bioavailability of hydrophobic molecules is to use fatty acids as solubility and encapsulation agents. Long chain-alkyl groups of fatty acids interact with the target molecule, leaving the hydrophilic carboxylic acid end of the fat molecule to interact with aqueous media. Collaborator is a Canadian (BC) company focused on a proprietary technology for producing formulations and compositions infused with lipophilic active agents (LAAs) and bioavailability enhancing agents (BEAs). Products formulated through this process are believed to confer advantages beyond increased bioavailability, such as taste-masking properties. Potential LAAs include a diverse range of specialty and functional ingredients, such as cannabinoids, nicotine, non-steroidal anti-inflammatory drugs and vitamins. Potential BEAs include any edible oil (e.g. sunflower oil), fat or material (e.g. non-fat dry milk) capable of forming a protective colloid with an LAA. Collaborator is currently most active in the delivery of hemp oil compounds in food and beverage compositions under the Lexaria Energy and ViPova brands, but has formed development agreements with other industry and commercialization partners to explore other applications for their patented processes in nutrition and health and wellness markets. A better understanding of the chemical nature of the LAAs in the presence of BEAs would provide valuable insight into process improvements and new product applications.
  
 Collaboration Overview 
NRC and Collaborator have common interests in the development of specialty and functional ingredients for differentiated consumer markets involving functional food, nutrition, and health and wellness applications. Both parties share expertise in fatty acid chemistry, product formulation and functional ingredient characterization, most notably cannabinoids and related active ingredients. This common interest creates a foundation for a strategic R&D relationship with the broad objectives of: 
  
 	 1. 
	 To develop specific Projects to explore solutions for the technical challenges surrounding commercialization of LAA- BEA formulations, both those common to the industry as a whole and those specific to Collaborator’s proprietary processes.

		  

	 2. 
	 To improve expertise and capacity in the area of ingredient formulation for improved product function, most notably cannabinoids and related high value bioactives.

		  

	 3. 
	 To identify and explore innovative new technologies and applications of mutual interest to NRC and Collaborator.

 
 
 
 
  
 Timeline 
The Collaboration will encompass 18 months beginning in January 2017.
  
 	 (2016) 
	 Page 11 of 14
	 NRC: ACRD: BSC 

		   
	 Business Confidential - Protected B 

 
 
 
 
 	 
	
	

	 

 
 
 
 
  
  
 	 
	 National Research Council 
	 Conseil national de recherches 
	 Master Collaborative

	 Canada 
	 Canada 
	 Research Agreement

 
 
 
 
  
 APPENDIX 1 
  
 PROJECT ANNEX (“PA”) # ___ 
  
 	 BETWEEN:
	 NATIONAL RESEARCH COUNCIL OF CANADA

	   
	 whose head office address is: 

 
 
 
 
  
 	  
	 1200 Montreal Road 
	
	  
	 Ottawa, ON K1A 0R6 
	 (called “NRC”) 

 
 
 
 
  
 	 AND:
	 LEXARIA CANPHARM CORP.

	   
	 whose address is: 

 
 
 
 
  
 	  
	 156 Valleyview Road 
	
	  
	 Kelowna, BC V1X 3M4 
	 (called the “Collaborator”) 

 
 
 
 
  
 	 1.
	 This PA is subject to the terms of the Master Collaborative Research Agreement (“Agreement”) between the Parties with an effective date of. 

		  

	 2
	 This PA concerns the following Project: 

	  
	  

	  
	  

	  
	  

		
		  

	 3.
	 The Parties shall contribute to the Project by the performance of work as described in the attached "Statement of Work and Deliverables”. 

		  

	 4.
	 The total price of the Project is estimated to be $ , which includes the following contributions from NRC and the Collaborator: 

 
 
 
 
  
 	  
	 4.1
	 NRC shall make a co-investment in the Project by performing, at its own cost, work as described in the Statement of Work and Deliverables at an estimated value of $ ________________. 

			
	  
	 4.2
	 The Customer shall pay to NRC in cash the sum of $ _____________, in accordance with Schedule of Payments outlined in clause 4.4. In addition the Customer shall pay all applicable taxes.* 

			
	  
	 4.3
	 The Collaborator shall make a co-investment in the Project by performing, at its own cost, work as described in the Statement of Work and Deliverables at an estimated value of $ ________________. 

			
	  
	 4.4
	 NRC will invoice the Collaborator for PA # ______ as follows: 

 
 
 
 
  
 	 SCHEDULE OF PAYMENTS
	  
	 AMOUNT DUE (CAD) 
Plus applicable taxes*

	 1. Invoice to be issued 
	  
	 $______ 

	 2. Invoice to be issued 
	  
	 $______ 

	 3. Invoice to be issued 
	  
	 $______ 

	 4. Invoice to be issued 
	  
	 $______ 

 
 
 
 
  
 	 5. 
	 This PA shall become effective on ____________________________________ and expires on ____________________________________. If the Deliverables are not completed by the expiration date, the Parties shall negotiate an extension to this PA prior to its expiry. Such extension shall be in writing and shall be signed by the authorized representatives of each Party. 

 
 
 
 
 _________________
 	 * 
	 Sales Tax (GST or similar) : NRC registration number 121 491 807 

	  
	 Quebec Sales Tax : NRC registration number 1006 178 088

 
 
 
 
  
 	 (2016) 
	 Page 12 of 14
	 NRC: ACRD: BSC 

		   
	 Business Confidential - Protected B 

 
 
 
 
 	 
	
	

	 

 
 
 
 
   
 	 
	 National Research Council 
	 Conseil national de recherches 
	 Master Collaborative

	 Canada 
	 Canada 
	 Research Agreement

 
 
 
 
  
 	 6.
	 Any rights and obligations under the Agreement or this PA which are intended to survive expiration or termination of a PA shall survive such expiration or termination.

		  

	 7.
	 In the event of any conflict between the Agreement and this PA, the Agreement shall take precedence.

 
 
 
 
  
 IN WITNESS WHEREOF, the Parties have signed this PA in duplicate copies. 
  
 	 NATIONAL RESEARCH COUNCIL OF CANADA
	  
	 LEXARIA CANPHARM CORP.
	  

	  
	 		 
	 By:
		 	 By:
		 
	  
	  
	  
	  
	  
	  

	 Name:
		 	Name		 
	  
	  
	  
	  
	  
	  

	 Title:
		 	Title:		 
	  
	  
	  
	  
	  
	  

	 Date:
	  
	  
	 Date:
	  
	  

 
 
  
   
 	 (2016) 
	 Page 13 of 14
	 NRC: ACRD: BSC 

		   
	 Business Confidential - Protected B 

 
 
 
 
 	 
	
	

	 

 
 
 
 
  
 	 
	 National Research Council 
	 Conseil national de recherches 
	 Master Collaborative

	 Canada 
	 Canada 
	 Research Agreement

 
 
 
 
  
 APPENDIX 2
  
 STATEMENT OF WORK AND DELIVERABLES 
  
 Project Annex (PA) #: 
  
 Objective of the Project 
  
 Work Plan Description 
  
 Materials, Equipment and Facilities Information 
  
 Deliverables 
  
 Project Estimated Budget 
  
 Project Plan and Schedule 
  
 Project Risks / Conditions 
  
 	 (2016) 
	 Page 14 of 14
	 NRC: ACRD: BSC 

		   
	 Business Confidential - Protected Blxrp_ex104.htm

EXHIBIT 10.4
  
 MANAGEMENT SERVICES AGREEMENT 
  
 THIS AGREEMENT dated for reference the 19th day of June 2017. 
  
 BETWEEN:
  
 	 Lexaria Bioscience Corp.., a company duly incorporated under the laws of the State of Nevada and having its office at 156 Valleyview Rd, Kelowna BC Canada V1X 3M4 

	  

	 (hereinafter referred to as the “Company”) 

  
 OF THE FIRST PART 
  
 AND 
  
 	 Phil Ainslie, PhD, Professor and Canada Research Chair in Cerebrovascular Physiology, University of British Columbia Okanagan and having an office at 3333 University way, Kelowna BC Canada V1V 1V7 

	  

	 (hereinafter referred to as “the Consultant” or “Consultant”) 

  
 WHEREAS: 
  
 	 A. 
	 The Company wishes to employ Consultant as its Advanced Education Research Manager on the terms and conditions hereinafter set forth, effective June 19, 2017.

		  

	 B. 
	 Consultant has agreed to provide the Services to the Company on the terms and conditions set out in this Agreement. This Agreement dated June 19, 2017, supersedes any other previous agreements between the Parties.

  
 NOW THEREFORE THIS AGREEMENT WITNESSES THAT in consideration of the premises and of the covenants and agreements hereinafter contained the parties hereto have agreed as follows: 
  
 	 1. 
	 ENGAGEMENT OF SERVICES

		  

	 1.1. 
	 The Company hereby engages Consultant to provide Services as an independent contractor to the Company under the direction of the chief executive officer and president; and

  
 	 1.2. 
	 Consultant hereby agrees to perform the following duties required of him, in a part-time position expected to average 10 hours per week, in accordance with the terms of this agreement namely:

  
 	  
	 (a) 
	 Initiate and complete grant-writing to obtain financial support for Consultant/Company research studies. In consultation with the Company President and CEO, design and manage R&D programs designed to investigate the Company’s technology and products, including but not limited to; nitric oxide and endothelial function response to ingestion of Company products and of products/substance processed with Company technology; pharmacokinetic and pharmacodynamic/performance studies to evaluate effectiveness and timeliness of human absorption of Company products, and of products/substances processed with Company technology; manage and supervise lab personnel and others as required to achieve any of the above objectives; and any other duties that should be reasonably expected of an experienced Advanced Education Research Manager; 

  
 	 
	- 1 -
	

	 

  
 	  
	 (b) 
	 General Services. Consultant shall serve the Company (and/or such subsidiary or subsidiaries of the company as the Company may from time to time require) in such consulting capacity or capacities as may from time to time be determined by senior management of the Company and shall perform such duties and exercise such powers as may from time be determined by senior Company management, as an independent contractor. Consultant will work as needed with partners, shareholders and other stakeholders as required by the Company. Consultant shall fulfill all duties expected of a Advanced Education Research Manager of a biotechnology/bioscience company that should be reasonably expected by and at the pleasure of the Board of Directors (together with all other items within Section 1.2, the “Services”).

  
 	 2. 
	 TERM

  
 	 2.1. 
	 The initial term of this Agreement shall be for a period of twelve (12) months, commencing as of the 30th day of June 2017 and continuing month to month thereafter with all terms in effect unless and until terminated as hereinafter provided. A results-based evaluation and performance assessment will be carried out at the six-month mark to determine whether results acceptable to the Company has been achieved. A results-based evaluation and performance assessment will be carried out at the twelve-month mark to determine whether results acceptable to the Company has been achieved in which case this Agreement would be expected to continue on a month-to-month basis or on terms then to be negotiated.

  
 	 3. 
	 SERVICES

  
 	 3.1 
	 Consultant agrees to perform the Services contracted hereunder including the following:

  
 	  
	 (a) 
	 to carry out all functions associated with the Services to the best of his skill and ability for the benefit of the Company;

			
	  
	 (b) 
	 to carry out the Services in a timely manner;

			
	  
	 (c) 
	 to work exclusively for the Company and to not work for other public companies during the time of engagement under this Agreement;

			
	  
	 (d) 
	 to act, at all times during the term of this Agreement, in the best interests of the Company; and

			
	  
	 (e) 
	 to use his best endeavors to preserve the goodwill and reputation of the Company and the relationship between the Company and its shareholders.

  
 	 
	- 2 -
	

	 

   
 	 4. 
	 REMUNERATION

  
 	  
	 4.1. 
	 The Company shall pay to Consultant for all Services rendered hereunder:

			
	  
	 4.2. 
	 the sum of three-thousand, eight-hundred and fifty-four dollars (CDN$3,854.17) plus Harmonized Sales Tax (HST) per month payable the last day of each calendar month, together with any such increments or bonuses thereto as the CEO or the President of the Company may from time to time determine.

			
	  
	 4.3. 
	 Consultant’s out of pocket expenses incurred on behalf of the Company shall be paid by the Company. Examples would include but not be limited to: normal day to day office operational expenses, client/shareholder/investor entertainment, and travel but not including home office rent. In respect of expenses, Consultant shall provide statements and vouchers to the Company on a monthly basis and it is expressly agreed that expenses for which no receipt is provided will be disallowed. Monthly expenses are capped at $1,000 without written (email or other) approval in advance from either the chief executive officer or president.

  
 	 5. 
	 INTELLECTUAL PROPERTY

  
 	 5.1. 
	 Company Intellectual Property: the Company retains full, absolute, and complete rights to all processes covered or described in all of their issued patents and patent applications filed prior to the date of this Letter of Intent, and any future continuations, continuations in part or divisional applications filed thereto, including but not limited to the US Provisional patent applications, US Utility patent applications, and the International and national patent applications thereunder (the “Technology” or the “Company IP”), unless the Company allows these applications to abandon or lapse, or otherwise fails to protect the Technology .

		  

	 5.2. 
	 Consultant Intellectual Property: Any existing intellectual property resulting from the Consultant’s prior work, know-how, or development that does not include or rely upon the Technology, Company IP or jointly owned intellectual property, shall be owned by the Consultant (“Consultant IP”).

		  

	 5.3. 
	 Improvements: The entire right and title to the Technology, whether or not patentable, and any patent applications or patents based thereon, which directly relate to and are not severable from the Company IP and which are improvements thereto by the Company, the Consultant, its employees or others acting solely on the Company’s behalf under shall be owned solely by the Company. Rights and title to improvements whether or not patentable, and any patent applications or patents based thereon, which directly relate to and are not severable from the Company IP and which are improvements thereto by the Consultant, its employees or associates, and which are learned or discovered as a result of work conducted under this Agreement, shall be owned by the Company.

  
 	 6. 
	 TERMINATION

  
 	 6.1. 
	 This Agreement may be terminated by either party at any time by sixty (60) days notice in advance, in writing given by Consultant to the Company, or by the Company to Consultant.

  
 	 
	- 3 -
	

	 

   
 	 6.2. 
	 The Company may terminate this Agreement at any time, without further obligation to Consultant if Consultant breaches any of the terms and conditions of this Agreement.

  
 	 7. 
	 NOTICE

  
 	 7.1. 
	 Any notice to be given under this Agreement shall be in writing and shall be deemed to have been given if delivered to, or sent by prepaid registered post addressed to, the respective addresses of the parties appearing on the first page of this Agreement (or to such other address as one party provides to the other in a notice given according to this paragraph). Where a notice is given by registered post it shall be conclusively deemed to be given and received on the fifth day after its deposit in a Canada post office any place in Canada.

  
 	 8. 
	 TAXES

  
 	 7.1 
	 Consultant shall be responsible for the payment of its income, capital gains and all other taxes and other remittances including but not limited to any form of insurance as shall be required by any governmental entity (including but not limited to health insurance and federal and state or provincial income taxes), though not including Director’s and Officer’s insurance which is paid for and provided by the Company, with respect to compensation paid by the Company to Consultant, and nothing in this Agreement implies or creates a relationship of employment. Consultant agrees to indemnify the Company for any tax, insurance or other remittance Consultant fails to make and which the Company may be obligated to pay. 

  
 	 9. 
	 MISCELLANEOUS

  
 	 8.1 
	 This Agreement may not be assigned by either party without the prior written consent of the other.

		  

	 8.2 
	 The titles of headings to the respective paragraphs of this agreement shall be regarded as having been used for reference and convenience only.

		  

	 8.3 
	 This Agreement shall enure to the benefit of and be binding upon the parties hereto and their respective heirs, executors, administrators, successors and permitted assigns.

		  

	 8.4 
	 This Agreement shall be governed by and interpreted in accordance with the laws of British Columbia, Canada.

		  

	 8.5 
	 Expenses. Consultant shall be reimbursed for all travelling and other expenses actually and properly incurred by it in connection with its duties hereunder, not including commuting to the office that is the normal place of business. For all such expenses Consultant shall furnish to the Company statements, receipts and vouchers for such out-of-pocket expenses on a monthly basis. Consultant is pre-authorized to incur up to $1,000 per month, cumulatively, in relevant expenses. Amounts over $1,000 per month must be pre-approved by management of the Company in writing or will be disallowed. Both parties recognize that this amount may be increased or decreased without making changes to this document, provided the Company makes Consultant aware of the changed amount. 

  
 	 
	- 4 -
	

	 

   
 	 8.6 
	 Consultant shall not, either during the continuance of its contract hereunder or at any time thereafter, disclose the private affairs of the Company and/or its subsidiary or subsidiaries, or any secrets or intellectual property of the Company (together or separately and as described below, “Proprietary Information”) and/or its subsidiary or subsidiaries, to any person other than the those necessary to effect this Agreement, Directors of the Company and/or its subsidiary or subsidiaries or for the Company’s purposes and shall not (either during the continuance of its contract hereunder or at any time thereafter) use for its own purposes or for any purpose other than those of the Company any information it may acquire in relation to the business and affairs of the Company and/or its subsidiary or subsidiaries, unless required by law.

		  

	 8.7 
	 Proprietary Information as that term is used herein shall consist of the following:

  
 	  
	 a) 
	 all knowledge, data and information which Consultant may acquire from the documents and information disclosed to it by the Company, its employees, attorneys, consultants, independent contractors, clients or representatives whether orally, in written or electronic form or on electronic media including, by way of example and not by limitation, any products, customer lists, investor, banking or finance lists, supplier lists, marketing techniques, technical processes, formulae, inventions or discoveries (whether patentable or not), innovations, suggestions, ideas, reports, data, patents, trade secrets and copyrights, made or developed by the Company and related data and information related to the conduct of the business of the Company.

			
	  
	 b) 
	 Proprietary Information shall also include discussions with officers, directors, employees, independent contractors, attorneys, consultants, clients, finance sources, customers or representatives and the fact that such discussions are taking place.

			
	  
	 c) 
	 Proprietary Information shall not be directly or indirectly disclosed to any other person without the prior written approval of the Company.

			
	  
	 d) 
	 Proprietary Information may not be used during the period of this contract nor thereafter, for the betterment of any other commercial enterprise, company, project or person without the prior written approval of the Company.

			
	  
	 e) 
	 Proprietary Information shall NOT include matters of general public knowledge, information posted at any o the Company’s websites or in any Company public regulatory filing; information legally received or obtained by Consultant from a third party or parties without a duty of confidentiality, and information independently known or developed by Consultant without the assistance of the Company.

  
 	 8.8 
	 Consultant shall well and faithfully serve the Company or any subsidiary as aforesaid during the continuance of its contract hereunder and use its best efforts to promote the interests of the Company. At all times Consultant will maintain a high degree of professionalism and integrity as would be expected in keeping with his senior executive role as President. Consultant reserves the right to refuse any request from the Company which may, in his reasonable opinion, violate either Federal or State Laws in either the United States or Canada.

		  

	 8.9 
	 This Agreement may be terminated forthwith by the Company or Consultant without notice if either party breaches the Agreement. A breach may include, but is not limited to, the following:

  
 	  
	 a) 
	 The Company or Consultant shall commit any material breach of any of the provisions herein contained; or

			
	  
	 b) 
	 The Company or Consultant shall be guilty of any misconduct or neglect in the discharge of its duties hereunder; or

  
 	 
	- 5 -
	

	 

   
 	  
	 c) 
	 The Company or Consultant shall become bankrupt or make any arrangements or composition with its creditors; or 

			
	  
	 d) 
	 Consultant shall become of unsound mind or be declared incompetent to handle his own personal affairs; or 

			
	  
	 (e) 
	 The Company or Consultant shall be convicted of any criminal offence other than an offence which, in the reasonable opinion of the Board of Directors of the Company, does not affect his/their position as a Consultant or a director of the Company. 

  
 This Agreement may also be terminated by either party upon sixty (60) days written notice to the other. Should the Company terminate this agreement for a reason not enumerated in items 8.9(a), 8.9(b), 8.9(c), 8.9(d), or 8.9(e), Consultant will be entitled to all Milestone Payments, as they relate to transactions which were in process but had not yet closed at the date of his termination, to which he would have otherwise been entitled for a period of 60 days after the date of his notice of termination. 
  
 	 8.10 
	 In the event this Agreement is terminated by reason of default on the part of Consultant or the written notice of the Company, then at the request of the Board of Directors of the Company, Consultant shall forthwith resign any position or office which he then holds with the Company or any subsidiary of the Company. The provisions of Sections on Proprietary Information and on Confidentiality shall survive the termination or expiration of this Agreement. 

		  

	 8.11 
	 Upon Termination or expiration of this Agreement, for any reason, Consultant shall do the following: Consultant must return to Lexaria immediately, all correspondence, information, reports, emails, phone recordings or transcripts, notes, Consultant contact information and all other materials related to the work performed for Lexaria including all Proprietary Information during the contract period. 

  
 	  
	 a) 
	 All such materials and information as referred to in Section 8.7, above, are the exclusive property of the Company. After returning, transmitting or otherwise sending such information to Lexaria, Consultant must destroy any and all remaining copy (ies) or records of same. Investor lists, banker and broker lists, and shareholder lists whether provided by Lexaria or developed by Consultant, if used by Consultant during activities provided under this Agreement, are the exclusive property of Lexaria any may not be used nor contacted in any manner by the Consultant for any non-Lexaria purpose either during the term of the this Agreement nor for two years following the expiration of this Agreement.

			
	  
	 b) 
	 All such materials and information as referred to in Section 12 were obtained during the time of the paid contract with Lexaria, and may not be shown, lent, given, discussed or in any way disclosed with or to any other party as per the terms of the contract. The Proprietary Information Consultant gained or had access to during the period of the contract is the exclusive property of Lexaria Corp, and the provisions governing such proprietary information survives the termination of this Consulting Agreement.

  
 	 8.12
	 The Company is aware that Consultant is independent and may have and may continue to have financial, management or business interests in other companies. The Company agrees that Consultant may continue to devote time to such outside interests, provided that such interests do not conflict with or hinder Consultant’s ability to perform his duties under this Agreement. 

		  

	 8.13 
	 The services to be performed by Consultant pursuant hereto are personal in character, to be performed by Mr. Philip Ainslie, and neither this Agreement nor any rights or benefits arising thereunder are assignable by Consultant without the previous written consent of the Company. 

  
 	 
	- 6 -
	

	 

   
 	 8.14 
	 With the exception of any previously granted options or restricted stock, any and all previous agreements, written or oral, between the parties hereto or on their behalf relating to the agreement between Consultant and the Company are hereby terminated and cancelled and each of the parties hereto hereby releases and forever discharges the other party hereto of and from all manner of actions, causes of action, claims and demands whatsoever under or in respect of any such previous agreements. 

		  

	 8.15 
	 Any notice in writing or permitted to be given to Consultant hereunder shall be sufficiently given if delivered to Consultant personally or mailed by registered mail, postage prepaid, addressed to Consultant at the address on the front of this Agreement. Provided any such notice is mailed via guaranteed overnight delivery, as aforesaid shall be deemed to have been received by Consultant on the first business day following the date of mailing. Any notice in writing required or permitted to be given to the Company hereunder shall be given by registered mail, postage prepaid, addressed to the Company at the address shown on page 1 hereof. Any such notice mailed as aforesaid shall be deemed to have been received by the Company on the first business day following the date of mailing provided such mailing is sent via guaranteed overnight delivery. Any such address for the giving of notices hereunder may be changed by notice in writing given hereunder. 

		  

	 8.16 
	 The provisions of this Agreement shall inure to the benefit of and be binding upon Consultant and the successors and assigns of the Company. For this purpose, the terms “successors” and “assigns” shall include any person, firm or corporation or other entity which at any time, whether by merger, purchase or otherwise, shall acquire all or substantially all of the assets or business of the Company. 

		  

	 8.17 
	 Every provision of this Agreement is intended to be severable. If any term or provision hereof is illegal or invalid for any reason whatsoever, such illegality or invalidity shall not affect the validity of the remainder of the provisions of this Agreement. 

		  

	 8.18 
	 This Agreement is being delivered and is intended to be managed from the Province of British Columbia and shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the laws of such Province. Similarly no provision within this contract is deemed valid should it conflict with the current or future laws of the United States of America or current or future regulations set forth by the United States Securities and Exchange Commission, the British Columbia Securities Commission, or the Ontario Securities Commission. This Agreement may not be changed orally, but only by an instrument in writing signed by the party against whom or which enforcement of any waiver, change, modification or discharge is sought. 

		  

	 8.19 
	 This Agreement and the obligations of the Company herein are subject to all applicable laws and regulations in force at the local, State, Province, and Federal levels in both Canada and the United States. In the event that there is an employment dispute between the Company and Consultant, Consultant agrees to allow it to be settled according to applicable Canadian law in an applicable British Columbia jurisdiction. 

		  

	 8.20 
	 This contract will expire on June 30, 2018 unless renewed or extended by mutual written consent of both parties prior to that date and can further serve as a month-to-month agreement after that date if both parties so agree at that time. 

		  

	 8.21 
	 Consultant understands and agrees that his name and likeness will be announced and widely circulated with regards to his role with the Company. His name will be disseminated through such avenues as press releases, websites, or other media; and in personal meetings and appearances and public events. Consultant understands that as a publicly traded entity, the Company has certain transparency obligations to its shareholders, stock exchanges, and other regulatory bodies, and has legal obligations to disclose Consultant’s initial and ongoing relationship with the Company during the normal course of business.

  
 	 
	- 7 -
	

	 

   
 IN WITNESS WHEREOF the parties have executed this Agreement the day and year first above written. 
  
 Lexaria Bioscience Corp: 
 
  
 	 Authorized Signatory 
	  

  
 	 SIGNED by: 
				
					
		  
	 DATED: 
		
					
	 
	  
	 June 13, 2017
		  

	 Philip Ainslie 
				

  
  
 	- 8 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]